Immunotherapy in GU Cancers

>

The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Latest News

Marjorie Green, MD, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories
Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

November 1st 2023

Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial.

Tian Zhang, MD, MHS
Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

RCC © stock.adobe.com
Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated Advanced Urothelial Cancer
Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated Advanced Urothelial Cancer

September 22nd 2023

Linda Wu, PhD
Preoperative APL-1202 Plus Tislelizumab Meets pCR Criteria, Moves to Next Stage of Trial in MIBC

September 13th 2023

Video Series
Video Interviews

More News